TOP > 外国特許検索 > PEPTIDE HAVING PROPERTY OF SPECIFICALLY ACCUMULATING IN GLIOMA, AND USE THEREOF

PEPTIDE HAVING PROPERTY OF SPECIFICALLY ACCUMULATING IN GLIOMA, AND USE THEREOF

外国特許コード F170009075
整理番号 (S2015-2036-N0)
掲載日 2017年5月29日
出願国 世界知的所有権機関(WIPO)
国際出願番号 2016JP081279
国際公開番号 WO 2017073485
国際出願日 平成28年10月21日(2016.10.21)
国際公開日 平成29年5月4日(2017.5.4)
優先権データ
  • 特願2015-211959 (2015.10.28) JP
発明の名称 (英語) PEPTIDE HAVING PROPERTY OF SPECIFICALLY ACCUMULATING IN GLIOMA, AND USE THEREOF
発明の概要(英語) The present invention provides a novel peptide having the property of specifically accumulating in and directly acting on a glioma. The present invention is a peptide represented by any one of the following (a) to (c): (a) a peptide formed from an amino acid sequence that includes a sequence represented by any one of SEQ ID NOs: 1, 2, and 3; (b) a peptide having the property of specifically accumulating in a glioma, and formed from an amino acid sequence that includes a sequence having undergone deletion, substitution or addition of one or more amino acids in an amino acid sequence represented by any one of SEQ ID NOs: 1, 2, and 3; and (c) a peptide having the property of specifically accumulating in a glioma, and formed from an amino acid sequence that includes a sequence at least 60% identical to a sequence represented by any one of SEQ ID NOs: 1, 2, and 3.
従来技術、競合技術の概要(英語) BACKGROUND ART
The frequency of occurrence is primary brain tumors, 10 million people per year per 1 population are said to human 10-15, of which 1/4 of the total surface area referred to as glioma tumor (glioma) group. High-grade gliomas among group classified as astrocytoma (grade 3) and leaves the forming five-year survival rate of about 23% and 5, glioblastoma and 10% (grade 4) is significantly lower. As glioma brain tissue penetrates into the existing Vth_TR infiltration since the characteristics of the tumor lesions, diagnosis by biopsy to determine or craniotomy surgery, radiation therapy including as much as possible in the tumor boundary precise diagnostic information of the pathological lesion portion is required. The current with respect to the central nervous system disease (lesions in the brain) as image information can be provided the highest accuracy as a test or diagnostic method, for example, in combination with the contrast agent, computed tomography (Computed Tomography: CT), magnetic resonance imaging (Magnetic resonance imaging: MRI), positron emission tomography (Positron Emission Tomography: PET) and the inspection method of the method or the like. More precisely as a method for acquiring information image diagnosis, for example fluorodeoxyglucose (fluorodeoxy glucose: FDG) - PET method and the like.
However, the peptide is utilized as a biomaterial in the trend in the medical field, Tat, penetratin, polyarginine such as a cell-membrane permeable peptide (cell-absorbable) is drawing attention. However, these peptides, tumor cells or normal cells or normal tissue and tumor tissue as well as the diffuse and non-selectively absorbed, requires the delivery of drug target selection to the treatment of malignant tumors (Drag Delivery System) apply the tool DDS, cause serious side effects in use difficult. In particular, worldwide Tat on a general-purpose experimental system such as a cell-membrane permeable (a cell-absorbable) peptide, the nature that gives rise to the liver has been known (for example, see non-patent document 1). On the other hand, the cyclic RGD, has been the only peptide pharmaceutical. Is cyclic RGD, neovascularization or existing in a blood vessel endothelial cells (and in some tumor cells) is highly expressed in reported αv β3 which targets integrin, upregulation of vascular permeability due to its action point, alone or in combination with other pharmaceutical without simultaneous imaging agents in the form or have been applied as DDS (for example, see Patent Document 1.).
  • 出願人(英語)
  • ※2012年7月以前掲載分については米国以外のすべての指定国
  • NIIGATA UNIVERSITY
  • 発明者(英語)
  • KONDO Eisaku
  • SAITO Ken
国際特許分類(IPC)
指定国 National States: AE AG AL AM AO AT AU AZ BA BB BG BH BN BR BW BY BZ CA CH CL CN CO CR CU CZ DE DJ DK DM DO DZ EC EE EG ES FI GB GD GE GH GM GT HN HR HU ID IL IN IR IS JP KE KG KN KP KR KW KZ LA LC LK LR LS LU LY MA MD ME MG MK MN MW MX MY MZ NA NG NI NO NZ OM PA PE PG PH PL PT QA RO RS RU RW SA SC SD SE SG SK SL SM ST SV SY TH TJ TM TN TR TT TZ UA UG US UZ VC VN ZA ZM ZW
ARIPO: BW GH GM KE LR LS MW MZ NA RW SD SL SZ TZ UG ZM ZW
EAPO: AM AZ BY KG KZ RU TJ TM
EPO: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
OAPI: BF BJ CF CG CI CM GA GN GQ GW KM ML MR NE SN ST TD TG
ライセンスをご希望の方、特許の内容に興味を持たれた方は、下記「問合せ先」までお問い合わせください。

PAGE TOP

close
close
close
close
close
close